Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Don't Forget Your Condoms At Birmingham Pride, Says Terrence Higgins Trust
HIV and sexual health charity Terrence Higgins Trust (THT) is joining forces with other local HIV organisations to remind visitors to Birmingham Pride (23 - 24 May) not to put their sexual health at risk by getting carried away with the party mood.

Lawsuit Filed Over Gene Patent
A group of cancer patients, genetic researchers and professional pathologist organizations has filed a lawsuit against Myriad Genetics and the U.S. Patent Office over the patent of two genes associated with an increased risk of breast and ovarian cancers, the New York Times reports. According to the Times, the government more than 10 years ago granted Myriad the patent on the BRCA1 and BRCA2 genes, as well as the company"s genetic test that measures a patient"s risk for the cancers.The lawsuit was filed by the American Civil Liberties Union and is believed to be the first of its kind, the Times reports. The lawsuit challenges the decision to grant patents on genes to Myriad and companies like it. The plaintiffs say that patents on genes restrict medical and research efforts, while companies like Myriad have said that the patent system supports innovation by giving them a temporary monopoly after they make a discovery, thereby rewarding prior investment in research and development.Wendy Chung, the director of clinical genetics at Columbia University and a plaintiff in the case, said, "With a sole provider, there"s mediocrity." The plaintiffs say that BRCA testing would improve with market competition. Furthermore, some plaintiffs argue that certain natural materials cannot be patented. Jan Nowak, president of the Association for Molecular Pathology and a plaintiff in the case, said, "You can"t patent my DNA, any more than you can patent my right arm, or patent my blood."To date, two government panels, including the National Research Council, found no evidence that gene patents result in significant impediments to research or medical care (Schwartz, New York Times, 5/13).
News of the day
Where The Most Private Becomes Public: Policy Making For Sexual Health
It is time to realign research and policy making to promote better sexual
Public Health

StemCells, Inc. To Present Phase I Clinical Trial Results At The 12th International Congress On NCL

StemCells, Inc. (NASDAQ:STEM) announced plans to present data from its Phase I clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) at the 12th International Congress on Neuronal Ceroid Lipofuscinoses (NCL) being held June 3 - 6, 2009 in Hamburg, Germany. Stephen Huhn, MD, FACS, FAAP, vice president and head of the Company"s CNS program, is scheduled to present the data on Saturday, June 6. The six-patient Phase I trial, conducted at Oregon Health & Science University Doernbecher Children"s Hospital, was designed primarily to assess the safety associated with transplanting HuCNS-SC cells as a treatment for infantile and late infantile NCL, often referred to as Batten disease. About Neuronal Ceroid Lipofuscinosis (Batten Disease) Neuronal ceroid lipofuscinosis is a fatal neurodegenerative disorder that afflicts infants and young children. The disorder is caused by genetic mutations, and children who inherit the defective gene are unable to produce enough of an enzyme that processes cellular waste substances that accumulate in a part of cells known as the lysosome. Without the enzyme, the cellular waste builds up, and eventually the cells cannot function and die. Children with NCL appear healthy when born, but as their brain cells die, they begin to suffer seizures and progressively lose motor skills, sight and mental capacity. Eventually, these children become blind, bedridden and unable to communicate or function on their own. There currently is no cure for the disease. The infantile and late infantile forms of NCL are caused by different genetic mutations. As the names imply, the two forms begin to afflict patients at different stages of infancy, but both have similar disease progression and outcomes. About HuCNS-SC® Cells StemCells" lead product candidate, HuCNS-SC cells, is a purified composition of normal human neural stem cells that are expanded and stored as banks of cells. The Company"s preclinical research has shown that HuCNS-SC cells can be directly transplanted; they engraft, migrate, differentiate into neurons and glial cells; and they survive for as long as one year with no sign of tumor formation or adverse effects. These findings show that HuCNS-SC cells, when transplanted, act like normal stem cells, suggesting the possibility of a continual replenishment of normal human neural cells. StemCells, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009